Latest Lead News

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

Elph Investments has secured a 92.68% stake in Engenco, making its 31-cent takeover offer unconditional and prompting the board to urge shareholders to accept before the June 27 deadline.

Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.

Odyssey Gold Commitments Limited has secured $4 million through a share placement to accelerate drilling and development at its Tuckanarra Gold Project, aiming to unlock near-term production potential.

Lode Resources has announced a maiden Mineral Resource Estimate for its Webbs Consol project in New South Wales, revealing a high-grade silver equivalent resource of 32 million ounces. The estimate confirms the project's potential with strong grades and promising metallurgical recoveries.

Transurban Group has announced a 33-cent ordinary dividend for the half-year ending June 2025, offering shareholders a fully franked, no-discount dividend reinvestment plan.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Minbos Resources has approved over A$800,000 in long lead item orders to advance Stage 2 construction of its Subantando Fertilizer Plant in Angola, supported by sovereign and development financing.

Zenith Minerals has opened a fully underwritten $3.5 million entitlement offer, inviting shareholders to subscribe for new shares with free attaching options, aiming to bolster its gold and lithium exploration projects.

Dreadnought Resources has reported promising assay results from recent drilling at its Mangaroon Gold Project, confirming extensions of shallow, high-grade gold mineralisation and setting the stage for further exploration.

Macmahon Holdings has locked in a new $550 million syndicated debt facility, extending maturity to 2029 with improved terms and robust bank backing. This refinancing positions the company for strategic growth while maintaining a conservative liquidity stance.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.